Table 1.
Clinicopathologic features of patients involved in this study.
| Characteristics | Total n=243 (%) |
|
|---|---|---|
| Age (years) | ≤60 | 152 (62.6) |
| >60 | 91 (37.4) | |
| Sex | Female | 92 (37.9) |
| Male | 151 (62.1) | |
| Primary tumor site | Colon | 154 (63.4) |
| Rectum | 89 (36.6) | |
| Primary tumor size (cm) | ≤4 | 114 (46.9) |
| >4 | 79 (32.5) | |
| Not available | 50 (20.6) | |
| T stage | 1 | 2 (0.8) |
| 2 | 18 (7.4) | |
| 3 | 139 (57.2) | |
| 4 | 84 (34.6) | |
| N stage | 0 | 105 (43.2) |
| 1 | 80 (32.9) | |
| 2 | 58 (23.9) | |
| Histological grade | Well/moderate | 208 (85.6) |
| Poor | 35 (14.4) | |
| Size of liver metastases (cm) | ≤2.5 | 131 (53.9) |
| >2.5 | 112 (46.1) | |
| Number of liver metastases | Single | 117 (48.1) |
| Multiple | 126 (51.9) | |
| Extrahepatic metastasis | Yes | 21 (8.6) |
| No | 222 (91.4) | |
| Hepatic resection timing | Metachronous | 118 (48.6) |
| Synchronous | 125 (51.4) | |
| Chemotherapy regimen before hepatic resection | Including irinotecan | 19 (7.8) |
| Including oxaliplatin | 55 (22.6) | |
| Others | 4 (1.6) | |
| No chemotherapy | 165 (67.9) | |
| Chemotherapy regimen after hepatic resection | Including irinotecan | 46 (18.9) |
| Including oxaliplatin | 125 (51.4) | |
| Others | 13 (5.3) | |
| No chemotherapy | 59 (24.3) | |
| RFA therapy a | Yes | 28 (11.5) |
| No | 215 (88.5) | |
| CEA level (ng/ml) b | ≤5 | 95 (39.1) |
| >5 | 148 (60.9) | |
| CA19-9 level (U/ml) c | ≤37 | 174 (71.6) |
| >37 | 69 (28.4) |
a Radiofrequency ablation therapy within 3 months before or after hepatic resection
b Carcinoembryonic antigen before hepatic resection
c Cancer antigen 19-9 before hepatic resection